ArticleHeliyon2023

Development and validation of a circulating tumor cells-related signature focusing on biochemical recurrence and immunotherapy response in prostate cancer.

Xuezhou Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.